ESPE Abstracts

Background: Central Precocious Puberty (CPP) may be lead to consequences such as limitation adult stature, sexual abuse, and emotional distress. GnRH agonist therapy in patients with CPP has been demonstrated in increasing adult height and improving emotional distress in puberty stage.

Objective: Evaluating the efficacy of treatment in patients with central precocious puberty after one year in Children Hospital 2, Vietnam in 7 years, from 01/2017 to 12/2016.

Methods: Cross sectional study, retrospective study 83 cases CPP which were treated minimum 1 year at Children Hospital 2 in 7 years, from 01/2017 to 12/2016.

Results: The secondary sex characteristics were almost reducing or suppressive, the menarche was disappeared in girls who had vaginal bleeding before. Mean height velocity decreased from 7 cm per year to 5.4 cm per year, BMI score increased significantly from 18.05 kg to 19 kg/ Basal LH, FSH and estradiol concentration had dropped sharply after 3 months. The difference between bone age and chronological age declined from 28 months to 25 months after 1 year. Bone mineral density, Calcium and vitamin D concentration was normal after 12 months. In General, the predicted adult height after and before treatment were no different significantly. However, in patients under 6 years old, the difference of predicted adult height between pre- and post- treatment was statistically significant (156.5–161.1 cm).

Conclusion: The secondary sex characteristics were almost reducing or suppressive. All patients had reduced height velocity and the difference between bone age and chronological age. Predicted adult height changed considerably in children under 6 years old